Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

A universal vaccine for serogroup B meningococcus.

Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M.

Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10834-9. Epub 2006 Jul 6.

2.

Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes.

Domnich A, Gasparini R, Amicizia D, Boccadifuoco G, Giuliani MM, Panatto D.

J Immunol Res. 2015;2015:353461. doi: 10.1155/2015/353461. Epub 2015 Aug 17. Review.

3.

The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.

Mameli C, Galli E, Mantegazza C, Fabiano V, Zuccotti GV.

Future Microbiol. 2015;10(10):1579-98. doi: 10.2217/fmb.15.91. Epub 2015 Oct 6. Review.

PMID:
26437903
4.

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).

Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R; members of the Canadian Immunization Monitoring Program, Active (IMPACT)..

Vaccine. 2013 Dec 17;32(1):124-30. doi: 10.1016/j.vaccine.2013.03.063. Epub 2013 Apr 12.

5.

[Active immunization against serogroup B Neisseria meningitidis].

Navarro-Alonso JA.

Enferm Infecc Microbiol Clin. 2003 Nov;21(9):513-9. Review. Spanish.

PMID:
14572386
6.

The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.

Zlotnick GW, Jones TR, Liberator P, Hao L, Harris S, McNeil LK, Zhu D, Perez J, Eiden J, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2015;11(1):5-13. doi: 10.4161/hv.34293. Epub 2014 Nov 1. Review.

7.

[New vaccines against group B meningococcal diseases].

Hietalahti J, Meri S.

Duodecim. 2015;131(6):525-32. Review. Finnish.

PMID:
26237895
8.

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.

Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, Medini D.

Vaccine. 2013 Oct 9;31(43):4968-74. doi: 10.1016/j.vaccine.2013.08.006. Epub 2013 Aug 14.

10.

Neisseria meningitidis B vaccines: recent advances and possible immunization policies.

Gasparini R, Amicizia D, Domnich A, Lai PL, Panatto D.

Expert Rev Vaccines. 2014 Mar;13(3):345-64. doi: 10.1586/14760584.2014.880341. Epub 2014 Jan 29. Review.

PMID:
24476428
11.

Reverse vaccinology--in search of a genome-derived meningococcal vaccine.

Danzig L.

Vaccine. 2006 Apr 12;24 Suppl 2:S2-11-2. Review.

PMID:
16823908
12.

Quadrivalent meningococcal conjugate vaccines.

Pace D, Pollard AJ, Messonier NE.

Vaccine. 2009 Jun 24;27 Suppl 2:B30-41. doi: 10.1016/j.vaccine.2009.05.003. Epub 2009 May 27. Review.

PMID:
19477560
13.
14.

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

Giuliani MM, Biolchi A, Serruto D, Ferlicca F, Vienken K, Oster P, Rappuoli R, Pizza M, Donnelly J.

Vaccine. 2010 Jul 12;28(31):5023-30. doi: 10.1016/j.vaccine.2010.05.014. Epub 2010 May 21.

PMID:
20493284
15.

A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).

Koeberling O, Ispasanie E, Hauser J, Rossi O, Pluschke G, Caugant DA, Saul A, MacLennan CA.

Vaccine. 2014 May 13;32(23):2688-95. doi: 10.1016/j.vaccine.2014.03.068. Epub 2014 Apr 3.

16.

New proteoliposome vaccine formulation from N. meningitidis serogroup B, without aluminum hydroxide, retains its antimeningococcal protectogenic potential as well as Th-1 adjuvant capacity.

Tamargo B, Márquez Y, Ramírez W, Cedré B, Fresno M, Sierra G.

BMC Immunol. 2013;14 Suppl 1:S12. doi: 10.1186/1471-2172-14-S1-S12. Epub 2013 Feb 25.

17.

Challenges and progress in the development of a serogroup B meningococcal vaccine.

Lewis S, Sadarangani M, Hoe JC, Pollard AJ.

Expert Rev Vaccines. 2009 Jun;8(6):729-45. doi: 10.1586/erv.09.30. Review.

PMID:
19485754
18.

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.

Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1302. doi: 10.1371/journal.pntd.0001302. Epub 2011 Sep 6.

19.

Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.

Bai X, Borrow R.

Expert Rev Vaccines. 2010 Oct;9(10):1203-17. doi: 10.1586/erv.10.116. Review.

PMID:
20923270
20.

Review of meningococcal group B vaccines.

Granoff DM.

Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S54-65. doi: 10.1086/648966. Review.

Supplemental Content

Support Center